Interpreting the impact of CDKN2A/B alterations on astrocytoma prognosis is complicated by recent changes in tumour classification and a lack of uniform standards for testing CDKN2A/B. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).